Background Drug-eluting stents (DES) are currently the most popular treatment modality for restenosis in bare metal stents and DES.This study compares risks of adverse cardiovascular events between DES-treated in-stent restenosis(ISR) and de novo lesions, an area that has not been systematically studied thus far.Methods 1300 consecutive ISR patients were compared with 27 211 patients with de novo lesions and who underwent DES treatment during the same period at the Fu Wai Hospital in Beijing.Propensity score matching analysis and multivariate regression analysis were performed.